Treatments in Ischemic Stroke: Current and Future
- PMID: 35917794
- DOI: 10.1159/000525822
Treatments in Ischemic Stroke: Current and Future
Abstract
Background and aim: Despite progress made over the last 30 years, stroke is still a leading cause of disability and mortality; likewise, its burden is expected to increase over the next decades, due to population growth and aging. The development of drugs with better safety-efficacy profiles as well as strategies able to improve ischemic stroke management from the pre-hospital setting is needed.
Summary: The pathophysiology of ischemic stroke involves multiple pathways resulting in cerebral artery obstruction and brain tissue ischemia. To date, the only approved drug for acute ischemic stroke is intravenous thrombolytic alteplase. Intravenous thrombolysis (IVT) can be administered alone or in combination with endovascular treatment (EVT) with mechanical thrombectomy, in case of large vessel occlusion and generally within 6 h from symptoms onset. The risk of potential bleeding complications, especially symptomatic intracerebral hemorrhage, is one of the reasons for the reluctance to administer IVT. Tenecteplase is a promising alternative fibrinolytic agent, having a better safety profile than alteplase. Moreover, recent evidences have allowed an extension of the IVT ± EVT time window for patients with unknown onset time and for those with a known onset time thanks to the new "tissue-window" approach guided by advanced neuroimaging techniques, which also helps in collateral circulation estimation. Regarding primary-secondary prevention, researchers are focused on improving the efficacy of antithrombotic drugs with a "hemostasis-sparing" approach. Neuroprotective agents are also under development, particularly stem cells. The COVID-19 pandemic has critically stressed global healthcare systems, with collateral damage resulting in access delivery of only emergency care, such as ischemic stroke. Regarding telemedicine, it has had a minor role in acute stroke management, and with the onset of COVID-19, this role will most likely be adopted to increase access and delivery in stroke assessment, but also in the follow-up.
Keywords: Acute ischemic stroke therapy; COVID-19; Ischemic stroke secondary prevention; Neuroprotection; Telestroke.
© 2022 S. Karger AG, Basel.
Similar articles
-
Tenecteplase or Alteplase Better in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion: A Single Center Observational Study.Medicina (Kaunas). 2022 Aug 28;58(9):1169. doi: 10.3390/medicina58091169. Medicina (Kaunas). 2022. PMID: 36143846 Free PMC article.
-
Early Recanalization Among Patients Undergoing Bridging Therapy With Tenecteplase or Alteplase.Stroke. 2023 Oct;54(10):2491-2499. doi: 10.1161/STROKEAHA.123.042691. Epub 2023 Aug 25. Stroke. 2023. PMID: 37622385
-
Advances in the management of acute ischemic stroke.Curr Opin Neurol. 2023 Apr 1;36(2):147-154. doi: 10.1097/WCO.0000000000001136. Epub 2023 Feb 7. Curr Opin Neurol. 2023. PMID: 36762632 Review.
-
Acute Treatment of Ischemic Stroke.Neurol Clin. 2022 Feb;40(1):17-32. doi: 10.1016/j.ncl.2021.08.002. Neurol Clin. 2022. PMID: 34798968 Review.
-
Advances in Acute Ischemic Stroke Therapy.Circ Res. 2022 Apr 15;130(8):1230-1251. doi: 10.1161/CIRCRESAHA.121.319948. Epub 2022 Apr 14. Circ Res. 2022. PMID: 35420919 Review.
Cited by
-
Gasdermin D could be lost in the brain parenchyma infarct core and a pyroptosis-autophagy inhibition effect of Jie-Du-Huo-Xue decoction after stroke.Front Pharmacol. 2024 Jul 29;15:1449452. doi: 10.3389/fphar.2024.1449452. eCollection 2024. Front Pharmacol. 2024. PMID: 39139639 Free PMC article.
-
Systemic Inflammatory Response Index and the Short-Term Functional Outcome of Patients with Acute Ischemic Stroke: A Meta-analysis.Neurol Ther. 2024 Aug 9. doi: 10.1007/s40120-024-00645-2. Online ahead of print. Neurol Ther. 2024. PMID: 39117893
-
Huanglian Jiedu decoction alleviates ischemia-induced cerebral injury in rats by mitigating NET formation and activiting GABAergic synapses.J Cell Mol Med. 2024 Aug;28(15):e18528. doi: 10.1111/jcmm.18528. J Cell Mol Med. 2024. PMID: 39099086 Free PMC article.
-
Research progress and challenges of stem cell therapy for ischemic stroke.Front Cell Dev Biol. 2024 Jul 8;12:1410732. doi: 10.3389/fcell.2024.1410732. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39040041 Free PMC article. Review.
-
Luteolin-7-O-β-d-glucuronide Ameliorates Cerebral Ischemic Injury: Involvement of RIP3/MLKL Signaling Pathway.Molecules. 2024 Apr 7;29(7):1665. doi: 10.3390/molecules29071665. Molecules. 2024. PMID: 38611943 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical